Abstract
From October 2014 there has been available a ""new"" per oral antibiotic for urinary tract infection in the Czech Republic - fosfomycin trometamol. This antibiotic, first described in 1969, is very effective to common urogenital pathogens include Gram positive cocci, but also to Gram negative bacteria with extended spectrum beta lactamase production.
The study from Faculty hospital Hradec Králové confirms high susceptibility (78.9-97.0 %) of tested urological pathogens (Escherichia coli, Klebsiella pneumoniae, Proteus sp., Enterobacter sp.). But from the literature there is well known the rapid resistance increase after the fosfomycin wide use Fosfomycin trometamol should be earmarked for the therapy of strains that are proven to nitrofurantoin insensitive and in particular strains of bacteria with the production of beta lactamase.